Changes over calendar time in the risk of specific first AIDS-defining events following HIV seroconversion, adjusting for competing risks.

BACKGROUND Although studies have reported large reductions in the risks of AIDS and death since the introduction of potent anti-retroviral therapies, few have evaluated whether this has been similar for all AIDS-defining diseases. We wished to evaluate changes over time in the risk of specific AIDS-defining diseases, as first events, using data from individuals with known dates of HIV seroconversion. METHODS Using a competing risks proportional hazards model on pooled data from 20 cohorts (CASCADE), we evaluated time from HIV seroconversion to each first AIDS-defining disease (16 groups) and to death without AIDS for four calendar periods, adjusting for exposure category, age, sex, acute infection, and stratifying by cohort. We compared results to those obtained from a cause-specific hazards model. RESULTS Of 6,941, 2,021 (29%) developed AIDS and 437 (6%) died without AIDS. The risk of AIDS or death remained constant to 1996 then reduced; relative hazard = 0.89 (95% CI: 0.77-1.03); 0.90 (95% CI: 0.81-1.01); and 0.32 (95% CI: 0.28-0.37) for 1979-1990, 1991-1993, and 1997-2001, respectively, compared to 1994-1996. Significant risk reductions in 1997-2001 were observed in all but two AIDS-defining groups and death without AIDS in a competing risks model (with similar results from a cause-specific model). There was significant heterogeneity in the risk reduction across events; from 96% for cryptosporidiosis, to 17% for death without AIDS (P < 0.0001). CONCLUSION These findings suggest that studies reporting a stable trend for particular AIDS diseases over the period 1979-2001 may not have accounted for the competing risks among other events or lack the power to detect smaller trends.

[1]  O. Kirk,et al.  Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy. , 2001, Blood.

[2]  A Muñoz,et al.  Methods to assess population effectiveness of therapies in human immunodeficiency virus incident and prevalent cohorts. , 2001, American journal of epidemiology.

[3]  C. Sabin The relationships between the HIV test interval, demographic factors and HIV disease progression , 2001, Epidemiology and Infection.

[4]  J. Margolick,et al.  Effectiveness of potent antiretroviral therapies on the incidence of opportunistic infections before and after AIDS diagnosis , 2001, AIDS.

[5]  A. Mocroft,et al.  AIDS across Europe, 1994–98: the EuroSIDA study , 2000, The Lancet.

[6]  S. Gange,et al.  Distinguishing efficacy, individual effectiveness and population effectiveness of therapies. , 2000, AIDS.

[7]  Hiv Survival,et al.  Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysis , 2000, The Lancet.

[8]  Kholoud Porter,et al.  Survival after introduction of HAART in people with known duration of HIV-1 infection , 2000, The Lancet.

[9]  R. Chaisson,et al.  Natural history of HIV infection in the era of combination antiretroviral therapy. , 1999, AIDS.

[10]  P Pezzotti,et al.  Temporal changes in the rate of progression to death among Italians with known date of HIV seroconversion: estimates of the population effect of treatment. Italian HIV Seroconversion Study (ISS). , 1999, Journal of acquired immune deficiency syndromes.

[11]  A. Telenti,et al.  Risk of HIV related Kaposi's sarcoma and non-Hodgkin's lymphoma with potent antiretroviral therapy: prospective cohort study , 1999, BMJ.

[12]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[13]  B. Yip,et al.  The incidence and spectrum of AIDS-defining illnesses in persons treated with antiretroviral drugs. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  JD Lundgren,et al.  Changing patterns of mortality across Europe in patients infected with HIV-1 , 1998, The Lancet.

[15]  A Muñoz,et al.  Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. , 1998, JAMA.

[16]  G. Satten,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.

[17]  Manuel Battegay,et al.  Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study , 1997, BMJ.

[18]  A. Muñoz,et al.  Models for the incubation of AIDS and variations according to age and period. , 1996, Statistics in medicine.

[19]  D. Clayton,et al.  Statistical Models in Epidemiology , 1993 .

[20]  Niels Keiding,et al.  Statistical Models Based on Counting Processes , 1993 .

[21]  M. T. Paixão,et al.  Expanded European AIDS case definition , 1993, The Lancet.

[22]  J. Kalbfleisch,et al.  The Statistical Analysis of Failure Time Data , 1980 .

[23]  Tx Station Stata Statistical Software: Release 7. , 2001 .

[24]  L. J. Wei,et al.  Regression analysis of multivariate incomplete failure time data by modeling marginal distributions , 1989 .

[25]  D. Cox Regression Models and Life-Tables , 1972 .

[26]  H. L. Le Roy,et al.  Proceedings of the Fifth Berkeley Symposium on Mathematical Statistics and Probability; Vol. IV , 1969 .

[27]  P. J. Huber The behavior of maximum likelihood estimates under nonstandard conditions , 1967 .